What Peptide Cycling Is Based On
Eight weeks on, four off. The advice is everywhere and the derivation is nowhere. Where the idea actually came from, and what the approved drugs do instead.
Almost every peptide protocol circulating online has an on-off structure, and almost none of them explains where the structure came from.
Eight weeks on, four weeks off. Five days on, two off. Twelve weeks, then an equivalent break. The numbers are stated with the confidence of a dosing table and they have the evidential status of a habit.
This is not an argument that cycling is wrong. It is an attempt to say plainly what it rests on, because the honest answer turns out to be more interesting than either “it works” or “it is nonsense.”
What the evidence actually contains
There are no controlled trials establishing that a particular on-off pattern improves outcomes, preserves response, or reduces harm for the compounds this advice is usually applied to.
Not “the trials are contested.” Not “the trials are small.” They were not run.
That absence has a specific shape worth understanding. Running such a trial would require a compound with enough regulatory standing to study in humans, a defined outcome, and a comparison between continuous and interrupted administration. For most of the compounds in question — BPC-157, TB-500, MOTS-c, Epitalon — the human evidence base does not reach the point where a scheduling question could even be asked.
So the cycling advice is not a conclusion drawn from weak data. It is a conclusion drawn from somewhere else entirely.
The three borrowings
From anabolic steroid practice
The on-off structure, and specifically the arithmetic of it, has the unmistakable shape of androgen cycle planning.
In that context the rationale is real and well described: exogenous androgens suppress the body’s own production through the hypothalamic-pituitary-gonadal axis, and the off period exists to allow recovery of that axis. There is a mechanism, it is specific, and the schedule addresses it.
The problem is that this mechanism belongs to androgens. It does not automatically exist for a peptide acting on an unrelated receptor with no comparable suppressive feedback loop. The structure migrated; the justification did not come with it.
From receptor desensitisation
This is the most respectable of the three, and it is the one worth taking seriously.
Desensitisation and tachyphylaxis are genuine. Continuous stimulation of some receptor systems does produce a diminishing response over time, through mechanisms including receptor internalisation and downregulation. Growth hormone secretagogues are a category where this concern is pharmacologically coherent rather than invented.
But there are three separate questions hiding inside one word. Does desensitisation occur for this compound? At the exposure actually being used? On a timescale that the proposed break would meaningfully reverse?
A general phenomenon existing in pharmacology answers none of those. For most compounds here, all three are open.
From precaution
The third rationale is the most honest and the least often stated: nobody knows what prolonged exposure to these compounds does, so less exposure seems safer than more.
That is a defensible position. It is also not a schedule. Precaution is a reason to limit total exposure; it does not generate eight weeks rather than six, or four weeks off rather than three. The specificity of the numbers is doing rhetorical work that the reasoning cannot support.
What the approved drugs do
Here the evidence is unambiguous, and it points the other way.
The labelled regimens for the approved GLP-1 receptor agonists involve ongoing weekly administration with a planned escalation to a maintenance dose. There is no scheduled off period. Tesamorelin, approved for HIV-associated lipodystrophy, is likewise given on a continuing basis.
These are the peptides for which the most is actually known, studied in the largest populations, over the longest durations, with the most scrutiny. They are dosed continuously.
This is not an argument that no peptide should ever be cycled. It is an observation that where the evidence base is strongest, the schedules that emerged from it are continuous — which is the opposite of what a reader would predict from the surrounding discourse.
Interrupting a labelled regimen is a decision with consequences of its own, and it belongs to the prescriber rather than to a protocol found online. The half-life of a compound sets what a gap actually does to exposure, and for the long-acting GLP-1s a missed interval is not a clean switch-off.
What follows
If a compound has an approved regimen, that regimen is the evidence, and it is continuous for the ones discussed here.
If a compound has no approved regimen, then a cycle is not a protocol derived from data. It is a precaution expressed as a number. That is a legitimate thing to choose — people make decisions under uncertainty constantly — but it should be chosen knowing what it is, rather than believing it came from a study.
What is not legitimate is the middle position: repeating a specific schedule as though it carried evidential weight, to someone who will reasonably assume it does.
The practical part
There is one thing that makes a cycle worth anything at all to the person running it, and it is not the schedule. It is the record.
A cycle is a claim about time. When it started, when it stopped, how long the gap actually ran, what changed across it. Reconstructed from memory eight weeks later, that claim is worthless — the start date drifts, the break gets rounded, and whatever was observed becomes unattributable.
Recorded, it is at least your own data. Not evidence in the sense a trial produces, but a real answer to “what did I actually do,” which is the minimum requirement for any conclusion at all.
The dates are the part worth keeping. They are also the part that survives least well in a notes app, which is the whole reason this is a hard problem rather than an obvious one.
Frequently asked questions
Is there evidence for cycling peptides on and off?
Not in the form people usually assume. There are no controlled trials establishing that a given on-off pattern improves outcomes or reduces harm for the compounds this advice is normally applied to. What exists is a set of borrowed rationales — from anabolic steroid practice, from receptor desensitisation pharmacology, and from general precaution about unknown long-term exposure. Each of those has some legitimate basis in its own domain. None of them was tested as a schedule for these compounds. The absence of evidence is not proof that cycling is pointless, but it does mean the specific numbers are not findings.
Where do numbers like "eight weeks on, four off" come from?
Nobody who repeats them can generally name a derivation, which is itself the informative fact. The pattern has the shape of anabolic steroid cycle planning, where the on-off structure addresses a specific and real endocrine problem — suppression of the body's own hormone production and the time needed to recover it. That mechanism is well described for androgens. It does not automatically exist for an unrelated peptide acting on a different receptor system. The numbers migrated across from a context where they meant something to one where their meaning has not been established.
What do the approved peptide drugs actually do?
They are dosed continuously, not in cycles. The labelled regimens for the approved GLP-1 receptor agonists involve ongoing weekly administration with a planned escalation to a maintenance dose, and no scheduled off period. Tesamorelin, approved for HIV-associated lipodystrophy, is likewise administered on an ongoing basis. This is the strongest evidence available on the question, and for those specific drugs it points away from cycling rather than towards it. Interrupting a labelled regimen is a decision with its own consequences and belongs to the prescriber.
Is receptor desensitisation a real reason to cycle?
Desensitisation and tachyphylaxis are real pharmacological phenomena, and for some receptor systems continuous stimulation does produce a diminishing response. That much is genuine. The gap is between the general phenomenon and the specific claim: whether it occurs for a particular peptide, at a particular exposure, on a timescale that a particular break would address, is a compound-specific empirical question. For most compounds discussed in this space, it has not been answered. "A real mechanism exists somewhere in pharmacology" is not the same as "this schedule fixes it here."